Oxabact is an investigational bi-modal enteric biotherapy containing a lyophilized formulation of Oxalobacter formigenes for the treatment of adults and children with primary hyperoxaluria (PH) of all types. The objective of the study is to treat PH and prevent or delay kidney deterioration.
OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced today that it has completed enrollment in its Oxabact ePHex phase III study.
Oxabact is an investigational bi-modal enteric biotherapy containing a lyophilized formulation of Oxalobacter formigenes for the treatment of adults and children with primary hyperoxaluria (PH) of all types. The objective of the study is to treat PH and prevent or delay kidney deterioration.
OxThera is on track to report top-line results from ePHex in mid 2021. The Company also announced completion of its 36-months Phase 2 clinical study in patients with PH and ESRD treated with intensive maintenance dialysis, and reiterated continued positive results previously presented at the 2020 American Society of Nephrology held in Washington, DC.
"We are pleased to have reached two important milestones for our Oxabact program in PH, timely completion of enrollment in ePHex – our 12-month Phase 3 pivotal study – and successful completion of our 36-month Phase 2 study with Oxabact in dialysis patients," said Matthew Gantz, CEO of OxThera. "We look forward to reporting topline results from the ePHex study in mid 2021. We believe that Oxabact has the potential to provide a clinically meaningful treatment option for patients living with PH."
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Severity: Warning
Message: count(): Parameter must be an array or an object that implements Countable
Filename: amp/news_details_amp.php
Line Number: 252
Backtrace:
File: /home/smartmarketnews/public_html/application/views/amp/news_details_amp.php
Line: 252
Function: _error_handler
File: /home/smartmarketnews/public_html/application/controllers/Amp_controller.php
Line: 41
Function: view
File: /home/smartmarketnews/public_html/index.php
Line: 315
Function: require_once
Smarter Decisions with Smart News
Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.
media@smartmarketnews.com | sales@smartmarketnews.com
Contact Us